Pacira BioSciences (PCRX) Share-based Compensation (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Share-based Compensation of $4.4 million for Q1 2026, down 70.07% year-over-year from $14.6 million in Q1 2025, and down 67.74% quarter-over-quarter from $13.5 million in Q4 2025.
Pacira BioSciences (PCRX) Share-based Compensation (2010 - 2026) Analysis & Trends
Pacira BioSciences' Share-based Compensation history runs 17 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 70.07% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $47.3 million (up 2398.89% YoY), while the FY2025 annual figure was $57.5 million, up 11611.2% from the prior year.
- Share-based Compensation for Q1 2026 stood at $4.4 million, down from $13.5 million in the prior quarter.
- The five-year high for Share-based Compensation was $15.5 million in Q2 2025, with the low at -$38.4 million in Q4 2024.
- The 5-year median for Share-based Compensation is $12.5 million (2024), against an average of $6.5 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation slumped 409.29% in 2024, then jumped 135.14% in 2025.
- Pacira BioSciences' Share-based Compensation stood at -$35.4 million in 2022, then jumped by 135.07% to $12.4 million in 2023, then plunged by 409.29% to -$38.4 million in 2024, then surged by 135.14% to $13.5 million in 2025, then sank by 67.74% to $4.4 million in 2026.
- Business Quant data shows PCRX's Share-based Compensation at $4.4 million in Q1 2026, $13.5 million in Q4 2025, and $14.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.31 Bn | 43.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.73 Bn | 40.08 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 32.22 Bn | 30.55 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.34 Bn | 19.68 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.89 Bn | 18.00 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.98 Bn | 11.45 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Pacira BioSciences | 951.23 Mn | 700.20 Mn | 148.24 Mn | 14.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.96 Mn |
| Jun 30, 2026 | 14.96 Mn |
| Mar 31, 2026 | 4.36 Mn |
| Mar 31, 2026 | 4.36 Mn |
| Dec 31, 2025 | 13.50 Mn |
| Dec 31, 2025 | 13.50 Mn |
| Sep 30, 2025 | 13.98 Mn |
| Sep 30, 2025 | 13.98 Mn |
| Jun 30, 2025 | 15.47 Mn |
| Jun 30, 2025 | 15.47 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Dec 31, 2024 | -38.41 Mn |
| Dec 31, 2024 | -38.41 Mn |
| Sep 30, 2024 | 13.23 Mn |
| Sep 30, 2024 | 13.23 Mn |
| Jun 30, 2024 | 12.52 Mn |
| Jun 30, 2024 | 12.52 Mn |
| Mar 31, 2024 | 13.15 Mn |
| Mar 31, 2024 | 13.15 Mn |